Dogwood Therapeutics reported cash from operations of -$3.61M and free cash flow of -$3.61M for the quarter ended Jun 2026, up 10.3% year over year. This cash flow statement covers 26 quarters of results from Mar 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||||||||||||||
| Net Income | -4.11M | -4.51M | -3.96M | -3.67M | -2.58M | -2.04M | -1.52M | -1.44M | -1.24M | -1.10M | -1.29M | -1.05M | -2.28M | -7.73M | -10.73M | -3.81M | -15.75M | -3.75M | -4.99M | -14.01M | ||||||
| Share-based Compensation | 0.75M | 0.13M | 0.75M | 1.05M | 1.01M | 0.15M | 1.62M | 1.65M | 1.65M | 0.15M | 0.14M | 2.03M | 0.09M | 0.09M | 0.08M | 0.19M | 0.33M | 0.16M | 1.76M | 5.32M | ||||||
| Deferred Taxes | -503.00 | 0.19M | 149.00 | -0.00M | 0.03M | 0.00M | -2.50M | |||||||||||||||||||
| Asset Writedowns and Impairment | 9.20M | |||||||||||||||||||||||||
| Cash from Operations | -2.65M | -5.18M | -2.66M | -3.66M | -2.48M | -2.67M | -1.70M | -0.74M | -0.96M | -1.47M | -0.94M | -0.81M | -0.91M | -6.13M | -4.68M | -4.03M | -3.27M | -3.64M | -4.59M | -3.61M | ||||||
| Depreciation, Depletion & Amortization | ||||||||||||||||||||||||||
| Amortizatization of Intangibles | 0.02M | 0.02M | 0.02M | |||||||||||||||||||||||
| Amortization of Deferred Charges | 0.05M | |||||||||||||||||||||||||
| Change in Working Capital | ||||||||||||||||||||||||||
| Change in Account Payables | 0.22M | -0.13M | -0.02M | 0.33M | -0.02M | -0.07M | -0.44M | 0.08M | -0.01M | -0.09M | 0.08M | -0.05M | 0.31M | -0.12M | -0.13M | -0.61M | 0.09M | 0.12M | -0.59M | 0.26M | ||||||
| Change in Accured Expenses | 0.62M | -0.31M | -0.33M | -0.43M | -0.06M | -0.11M | -0.02M | -0.04M | 0.13M | -0.09M | 0.60M | -0.93M | -0.18M | -0.01M | 0.50M | 0.30M | 0.19M | 0.03M | ||||||||
| Other Working Capital Changes | -1.01M | 0.85M | -0.57M | 0.15M | -0.28M | 0.27M | -0.15M | -0.57M | -0.16M | 0.39M | -0.00M | -0.23M | -0.37M | 1.10M | -0.07M | -0.32M | 0.23M | 0.38M | -0.29M | -0.36M | ||||||
| Financing Activities | ||||||||||||||||||||||||||
| Other financing activities | -0.49M | -0.09M | 132.00 | 23.00 | ||||||||||||||||||||||
| Debt Issuance and Repayment | ||||||||||||||||||||||||||
| Long-Term Debt Issuances | 3.00M | |||||||||||||||||||||||||
| Change in Capital Stock | ||||||||||||||||||||||||||
| Net Shares Issued and Repurchased | 0.23M | 0.29M | 0.91M | 0.00M | 0.02M | 0.02M | 1.04M | 0.66M | ||||||||||||||||||
| Net Equity Issued and Repurchased | 1.36M | |||||||||||||||||||||||||
| Misc. | ||||||||||||||||||||||||||
| Cash from Financing Activities | -0.09M | -0.07M | 15.32M | 7.37M | -0.12M | 0.03M | 11.29M | 23.00 | ||||||||||||||||||
| Exchange Rate Effect | 0.00M | 0.01M | -0.00M | 0.00M | -0.00M | -0.01M | ||||||||||||||||||||
| Change in Cash | -2.65M | -5.18M | -2.66M | -3.66M | 2.09M | -2.76M | -1.70M | -0.74M | 0.20M | -1.47M | -0.94M | 0.64M | -0.98M | 12.95M | 2.69M | -4.15M | -3.27M | -3.60M | 6.70M | -3.61M | ||||||
| Free Cash Flow | -2.65M | -5.18M | -2.66M | -3.66M | -2.48M | -2.67M | -1.70M | -0.74M | -0.96M | -1.47M | -0.94M | -0.81M | -0.91M | -6.13M | -4.68M | -4.03M | -3.27M | -3.64M | -4.59M | -3.61M | ||||||
| Net Cash Flow | -2.65M | -5.18M | -2.66M | -3.66M | -2.48M | -2.76M | -1.70M | -0.74M | -0.96M | -1.47M | -0.94M | -0.81M | -0.98M | 9.19M | 2.69M | -4.15M | -3.27M | -3.60M | 6.70M | -3.61M |